ARCT: Upcoming phase II data and a pivotal CF decision mark major milestones for the mRNA pipeline
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and regained global control of a leading COVID vaccine. Key near-term milestones include a phase II data readout for OTC deficiency and a pivotal phase III decision for the CF program, both with significant co…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.